Neurophth and Hopstem Partner to Develop Stem Cell Therapies for Eye Diseases

Neurophth, a Wuhan company developing gene therapies for ophthalmic diseases, will partner with Hangzhou 's Hopstem to develop a candidate using stem cells for ocular diseases including blindness. Hopstem has expertise in GMP manufacturing of clinical cell products derived from human induced pluripotent stem cells (hiPSC). It will receive upfront and milestone payments, plus royalties, to develop a candidate for a specific retinal degenerative disorder. Neurophth, which will have the option to license the candidate, will be responsible for its development and commercialization. More details.... Share this with colleagues: // //